Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023
mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI
VE hospital network
Egészségbiztonság Nemzeti Laboratórium(RRF-2.3.1-21-2022-00006) Támogató: NKFIH
We conducted a multicentre hospital‐based test‐negative case–control study to measure
vaccine effectiveness (VE) against PCR‐confirmed influenza in adult patients with
severe acute respiratory infection (SARI) during the 2022/2023 influenza season in
Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza.
Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36); 20% (95% CI: −4–39)
against A(H3N2) and 56% (95% CI: 22–75) against B. During the 2022/2023 season, while
VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A
subtypes. While influenza vaccination should be a priority for future seasons, improved
vaccines against influenza are needed.